Literature DB >> 11228033

Delivery systems for acute migraine medications.

I Worthington1.   

Abstract

OBJECTIVE: To discuss advantages and disadvantages of various routes of administration and delivery systems for acute migraine medications, and to assist family physicians in optimizing treatment for individual patients. QUALITY OF EVIDENCE: A MEDLINE search from January 1966 to October 2000 and a Current Contents search for the year 1999 to October 2000 were conducted. Randomized controlled trials were selected, when available. Also included are guidelines (Canadian), non-blinded trials, systematic reviews, and population-based studies. MAIN MESSAGE: Selecting an appropriate way to deliver medication is important in acute migraine therapy. The parenteral route has advantages, such as rapid onset, greater efficacy, and the possibility of use during nausea and vomiting. Disadvantages include local site discomfort, inconvenience, and patients' dislike of needles. Most patients prefer oral therapy, but gastric stasis and nausea and vomiting during a migraine attack might limit its use. The intranasal route usually provides fairly rapid onset, but side effects, such as disturbances in taste, can occur. The rectal route is another option, but absorption is sometimes erratic, rectal irritation can occur, and few migraine medications are available in rectal formulation.
CONCLUSION: Selection of appropriate medications and suitable delivery systems for individual patients, based on the characteristics of their attacks (e.g., severity, speed of progression to severe intensity, degree of associated symptoms), ease of administration, and patient preference, will optimize therapy for acute migraine attacks.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228033      PMCID: PMC2016250     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  30 in total

1.  Subacute angle-closure glaucoma as a cause of headache.

Authors:  P Lavin
Journal:  Headache       Date:  1999 Jul-Aug       Impact factor: 5.887

2.  Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial.

Authors:  R C Cady; R Ryan; P Jhingran; S O'Quinn; D G Pait
Journal:  Arch Intern Med       Date:  1998-05-11

3.  Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.

Authors:  S Diamond; A Elkind; R T Jackson; R Ryan; S DeBussey; M Asgharnejad
Journal:  Arch Fam Med       Date:  1998 May-Jun

4.  A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice.

Authors:  K Gruffydd-Jones; C A Hood; D B Price
Journal:  Cephalalgia       Date:  1997-02       Impact factor: 6.292

5.  Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.

Authors:  S P Ahrens; M V Farmer; D L Williams; E Willoughby; K Jiang; G A Block; W H Visser
Journal:  Cephalalgia       Date:  1999-06       Impact factor: 6.292

6.  Rizatriptan tablet versus wafer: patient preference.

Authors:  J U Adelman; L K Mannix; R L Von Seggern
Journal:  Headache       Date:  2000-05       Impact factor: 5.887

7.  Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department.

Authors:  E B Jones; E R Gonzalez; J G Boggs; J A Grillo; R K Elswick
Journal:  Ann Emerg Med       Date:  1994-08       Impact factor: 5.721

8.  Home administration of intramuscular DHE for the treatment of acute migraine headache.

Authors:  M A Weisz; M el-Raheb; H J Blumenthal
Journal:  Headache       Date:  1994-06       Impact factor: 5.887

9.  A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group.

Authors:  M S Kramer; D Matzura-Wolfe; A Polis; A Getson; P G Amaraneni; M P Solbach; W McHugh; J Feighner; S Silberstein; S A Reines
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society.

Authors:  W E Pryse-Phillips; D W Dodick; J G Edmeads; M J Gawel; R F Nelson; R A Purdy; G Robinson; D Stirling; I Worthington
Journal:  CMAJ       Date:  1998-07-14       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.